Abstract:RNA splicing, a crucial transesterification-based process by which noncoding regions are removed from premature RNA to create mature mRNA, regulates various cellular functions, such as proliferation, survival, and differentiation. Clinical and functional studies over the past 10 y have confirmed that mutations in RNA splicing factors are among the most recurrent genetic abnormalities in hematologic neoplasms, including myeloid malignancies, chronic lymphocytic leukemia, mantle cell lymphoma, and clonal hematopoiesis. These findings indicate an important role for splicing factor mutations in the development of clonal hematopoietic disorders. Mutations in core or accessory components of the RNA spliceosome complex alter splicing sites in a manner of change of function. These changes can result in the dysregulation of cancer-associated gene expression and the generation of novel mRNA transcripts, some of which are not only critical to disease development but may be also serving as potential therapeutic targets. Furthermore, multiple studies have revealed that hematopoietic cells bearing mutations in splicing factors depend on the expression of the residual wild-type allele for survival, and these cells are more sensitive to reduced expression of wild-type splicing factors or chemical perturbations of the splicing machinery. These findings suggest a promising possibility for developing novel therapeutic opportunities in tumor cells based on mutations in splicing factors. Here, we combine current knowledge of the mechanistic and functional effects of frequently mutated splicing factors in normal hematopoiesis and the effects of their mutations in hematologic malignancies. Moreover, we discuss the development of potential therapeutic opportunities based on these mutations.

Interplay Between Cofactors and Transcription Factors in Hematopoiesis and Hematological Malignancies.

FOXN Transcription Factors: Regulation and Significant Role in Cancer

Transcription factor genetics and biology in predisposition to bone marrow failure and hematological malignancy

The Role of Transcription Factors in the Crosstalk Between Cancer-Associated Fibroblasts and Tumor Cells.

Core transcriptional regulatory circuitries in cancer

Targeting Post-Translational Modification of Transcription Factors As Cancer Therapy.

Transcription Factors That Govern Development and Disease: An Achilles Heel in Cancer

Role of transcriptional cofactors in cardiovascular diseases

Hematopoietic Cytokines, Transcription Factors and Lineage Commitment

A comprehensive survey for human transcription factors on expression, regulation, interaction, phenotype and cancer survival

TCF21: a critical transcription factor in health and cancer

RNA Splicing Factors in Normal Hematopoiesis and Hematologic Malignancies: Novel Therapeutic Targets and Strategies

Targeting Key Proteins Involved in Transcriptional Regulation for Cancer Therapy: Current Strategies and Future Prospective.

The Role of CREBBP/EP300 and Its Therapeutic Implications in Hematological Malignancies

Complex Interdependence Regulates Heterotypic Transcription Factor Distribution and Coordinates Cardiogenesis

Altering chromatin methylation patterns and the transcriptional network involved in regulation of hematopoietic stem cell fate

Hematopoietic Stem Cell Transcription Factors in Cardiovascular Pathology

Integrated analysis of transcription factors and targets co-expression profiles reveals reduced correlation between transcription factors and target genes in cancer

Epigenetic Regulation in Hematopoiesis and Its Implications in the Targeted Therapy of Hematologic Malignancies

Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy

Tumor iron homeostasis and immune regulation